Skip to main content

Month: January 2022

Cloud Nine Web3 Technologies Retains Cryptocurrency Miner to Monetize Operations

Enters into service agreement that permits third party miner to access Cloud Nine’s unused computer processing power of its userbase for cryptocurrency mining Company continues to grow userbase through no-charge Limitless VPN (virtual private network) available at www.limitlessvpn.com Management anticipates commencing mining once userbase reaches 50,000 registered active usersVANCOUVER, British Columbia, Jan. 24, 2022 (GLOBE NEWSWIRE) — Cloud Nine Web3 Technologies Inc. (CSE: CNI) (OTC: CLGUF) (FRANKFURT: 1JI0) (“Cloud Nine” or the “Company”), a leading decentralized network and data storage technology company, announces it has entered into a third party services agreement with Argent Crypto, Inc., a British Columbia cryptocurrency based Money Services Business (the “Crypto MSB”), whereby the Crypto MSB has agreed to access...

Continue reading

DUET Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option

KUALA LUMPUR, MALAYSIA, Jan. 24, 2022 (GLOBE NEWSWIRE) — DUET Acquisition Corp. (Nasdaq: DUETU) (the “Company”) announced today the closing of its initial public offering of 7,500,000 units at $10.00 per unit (the “Offering”). Each unit consists of one of the Company’s Class A common stock and one redeemable warrant. Each warrant entitles the holder thereof to purchase one Class A common stock at a price of $11.50 per share. The underwriters exercised their over-allotment option in full for an additional 1,125,000 units at the time of the closing of the Offering. As a result, the aggregate gross proceeds of the Offering, including the over-allotment, is approximately $86.25 million, prior to deducting underwriting discounts, commissions, and other Offering expenses. The Company’s units began trading on the Nasdaq...

Continue reading

Verisk Announces Sale of 3E Business to New Mountain Capital

JERSEY CITY, N.J., Jan. 24, 2022 (GLOBE NEWSWIRE) — Verisk (Nasdaq: VRSK), a leading global data analytics provider, today announced that it has entered into a definitive agreement to sell its 3E business to New Mountain Capital, a growth-oriented investment firm with over $35 billion in assets under management, for a potential aggregate cash consideration of up to $950 million. Verisk’s 3E business, part of its energy and specialized markets segment, delivers intelligent compliance solutions that enable companies to manage global regulatory compliance, product stewardship risk and drive continuous improvement to support their environmental health and safety (EHS) initiatives. 3E offers industry-leading software and information services to 5,000 customers worldwide, including industry leaders across chemical manufacturing, retail...

Continue reading

Constellation Brands Announces Jim Sabia as President, Beer Division

Paul Hetterich assumes role of Chair, Beer Division as part of leadership transition VICTOR, N.Y., Jan. 24, 2022 (GLOBE NEWSWIRE) — Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, today announced new responsibilities for two members of its Executive Management Committee, effective immediately. Jim Sabia, who has served as Constellation’s Executive Vice President and Managing Director, Beer Division, since February 2021, will assume the role of Executive Vice President and President, Beer Division with day-to-day general management responsibilities for all U.S. commercial and operations functions related to the company’s beer business. Paul Hetterich will transition from his current responsibilities as Executive Vice President and President, Beer Division to assume the role of Executive Vice...

Continue reading

Opiant Pharmaceuticals Announces Additional $2.2 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program

SANTA MONICA, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (“BARDA”) for an additional commitment of up to $2.2 million to support OPNT003, nasal nalmefene, for opioid overdose. The increase in funding is primarily directed toward the costs of Opiant’s clinical studies to support its submission of OPNT003 to the Food and Drug Administration (“FDA”). Opiant is currently completing a non-inferiority pharmacodynamic (“PD”) study comparing nasal nalmefene with nasal naloxone in reversing respiratory depression produced by remifentanil, a synthetic opioid. In a confirmatory pharmacokinetic (“PK”) study, conducted last year, OPNT003 exhibited fast absorption and high plasma...

Continue reading

Hydrofarm and AXEON Water Technologies Enter Strategic Partnership

California-based water filtration manufacturer to distribute systems through Hydrofarm FAIRLESS HILLS, Pa., Jan. 24, 2022 (GLOBE NEWSWIRE) — Hydrofarm Holdings Group, Inc. (“Hydrofarm” or the “Company”) (Nasdaq: HYFM), a leading distributor and manufacturer of hydroponics equipment and supplies for controlled environment agriculture (“CEA”), announced it has entered into an agreement with California-based AXEON Water Technologies (“AXEON”), a leading manufacturer of water purification solutions, to distribute new lines of reverse osmosis water filtration systems and solutions for the horticultural market. The partnership between AXEON and Hydrofarm will allow for many of the nation’s top retailers and professionals to gain access to high-quality, technologically advanced purification systems and membrane filtration solutions. “AXEON...

Continue reading

89bio Reports Positive Topline Results from an Expansion Cohort of the Phase 1b/2a Trial of Pegozafermin (BIO89-100) for the Treatment of NASH

63% of patients achieved 2-point or greater improvement in NAS without worsening of fibrosis; clinically meaningful improvements on registration enabling endpoints of NASH resolution (32%) and fibrosis improvement (26%)Robust changes on multiple non-invasive liver tests, markers of cardiovascular health and glycemic control support pegozafermin’s potential as a compelling treatment option for NASHPhase 2b ENLIVEN trial ongoing in NASH patients with results expected in first half 2023Conference call and webcast today at 1:30 p.m. PST/4:30 p.m. ESTSAN FRANCISCO, Jan. 24, 2022 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced positive topline...

Continue reading

Capital Product Partners L.P. Announces Increased Cash Quarterly Distribution by 50% to $0.15

ATHENS, Greece, Jan. 24, 2022 (GLOBE NEWSWIRE) — Capital Product Partners L.P. (NASDAQ: CPLP) today announced that its board of directors has declared an increased cash distribution of $0.15 per common unit for the fourth quarter of 2021 ended December 31, 2021. This represents an increase by 50% compared to the common unit cash distribution announced for the previous quarter. The fourth quarter common unit cash distribution will be paid on February 10, 2022 to common unit holders of record on February 3, 2022. About Capital Product Partners L.P. Capital Product Partners L.P. (NASDAQ: CPLP), a Marshall Islands master limited partnership, is an international owner of ocean-going vessels. CPLP currently owns 21 vessels, including 11 Neo-Panamax container vessels, three Panamax container vessels, one Capesize bulk carrier and six...

Continue reading

Leslie’s, Inc. to Report First Quarter Fiscal 2022 Financial Results on February 3, 2022

PHOENIX, Jan. 24, 2022 (GLOBE NEWSWIRE) — Leslie’s, Inc. (“Leslie’s” or “Company”; NASDAQ:LESL), the largest and most trusted direct-to-consumer brand in the U.S. pool and spa care industry, today announced that its financial results for the first quarter of fiscal 2022 will be released after market close on Thursday, February 3, 2022. The Company will host a conference call at 4:30 p.m. Eastern Time to discuss the financial results. Investors and analysts interested in participating in the call are invited to dial 877-407-0784 (international callers please dial 1-201-689-8560) approximately 10 minutes prior to the start of the call. A live audio webcast of the conference call will be available online at https://ir.lesliespool.com/. A recorded replay of the conference call will be available within approximately...

Continue reading

Matrix Service Company Sets Date to Discuss Results for the Second Quarter of Fiscal 2022

TULSA, Okla., Jan. 24, 2022 (GLOBE NEWSWIRE) — Matrix Service Company (Nasdaq: MTRX) will announce results for its Fiscal Year 2022 second quarter after the market closes on Monday, February 7, 2022. The release will be followed by a conference call on Tuesday, February 8, 2022 at 10:30 a.m. Eastern time /09:30 a.m. Central time. Earnings Conference Call instructions Matrix Service Company will host a conference call with John R. Hewitt, President and CEO and Kevin S. Cavanah, Vice President and CFO at 10:30 a.m. Eastern Time / 09:30 a.m. Central Time on February 8, 2022. The call will be simultaneously broadcast live over the Internet, which can be accessed at the Company’s website at www.matrixservicecompany.com on the Investors Relations page under Events & Presentations. Please allow extra time prior to the call to visit...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.